{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:07:40Z","timestamp":1780621660084,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["13641.2"],"award-info":[{"award-number":["13641.2"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["15265.1"],"award-info":[{"award-number":["15265.1"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"Kommission f\u00fcr Technologie und Innovation","doi-asserted-by":"publisher","award":["19080.2"],"award-info":[{"award-number":["19080.2"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013348","name":"Innosuisse Swiss Innovation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bcp.2023.115504","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T21:31:07Z","timestamp":1678743067000},"page":"115504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Allosteric targeting resolves limitations of earlier LFA-1 directed modalities"],"prefix":"10.1016","volume":"211","author":[{"given":"Riccardo V.","family":"Mancuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisbert","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"H\u00fcrzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Zurfl\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Breitenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Bouitbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Atz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gygax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Weitz-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2023.115504_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115504_b0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.immunol.25.022106.141618","article-title":"Structural basis of integrin regulation and signaling","volume":"25","author":"Luo","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115504_b0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2023.115504_b0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17460441.2020.1819234","article-title":"How not to discover a drug - integrins","volume":"16","author":"Cox","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"119","key":"10.1016\/j.bcp.2023.115504_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcp.2016.09.002","article-title":"Downstream effect profiles discern different mechanisms of integrin \u03b1L\u03b22 inhibition","volume":"1","author":"Mancuso","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115504_b0035","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/bph.14996","article-title":"Anti-\u03b1L\u03b22 antibodies reveal novel endocytotic cross-modulatory functionality","volume":"177","author":"Mancuso","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115504_b0040","doi-asserted-by":"crossref","unstructured":"N.K. Verma, D. Kelleher, Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program, J. Immunol. 199 (4) (2017) 1213\u20131221, doi: 10.4049\/jimmunol.1700495.","DOI":"10.4049\/jimmunol.1700495"},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000518721","article-title":"VLA-4 as a central target for modulating neuroinflammatory disorders","volume":"28","author":"Jurberg","year":"2021","journal-title":"Neuroimmunomodulation"},{"issue":"2","key":"10.1016\/j.bcp.2023.115504_b0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sder.2010.01.001","article-title":"Assessing long-term drug safety: lessons (re) learned from raptiva","volume":"29","author":"Seminara","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"issue":"2","key":"10.1016\/j.bcp.2023.115504_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2051-5960-2-27","article-title":"\u03b14-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets","volume":"7","author":"Rothhammer","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2023.115504_b0065","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/jid.2008.4","article-title":"Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness","volume":"128","author":"Guttman-Yassky","year":"2008","journal-title":"J, Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2004.06.001","article-title":"Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin","volume":"113","author":"Vugmeyster","year":"2004","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0075","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.183.4.1415","article-title":"LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor","volume":"183","author":"Schmits","year":"1996","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12016-009-8132-3","article-title":"Defects in the leukocyte adhesion cascade","volume":"38","author":"Etzioni","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0085","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jaip.2017.12.008","article-title":"Leukocyte adhesion deficiency-I: A comprehensive review of all published cases","volume":"6","author":"Almarza Novoa","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.bcp.2023.115504_b0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocul. Surf."},{"issue":"9","key":"10.1016\/j.bcp.2023.115504_b0095","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1167\/iovs.10-5896","article-title":"Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy","volume":"52","author":"Faia","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2023.115504_b0100","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1167\/iovs.09-5144","article-title":"Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)","volume":"51","author":"Rao","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0002-9440(10)64643-3","article-title":"CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury","volume":"157","author":"Moromizato","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115504_b0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bcp.2023.115504_b0115","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/138161206777947731","article-title":"LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics","volume":"12","author":"Giblin","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"11","key":"10.1016\/j.bcp.2023.115504_b0120","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.jmedchem.9b01869","article-title":"Insights into protein-ligand interactions in integrin complexes: advances in structure determinations","volume":"63","author":"Zheng","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115504_b0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1074-7613(03)00238-3","article-title":"Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other","volume":"19","author":"Shimaoka","year":"2003","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bcp.2023.115504_b0130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.bcp.2023.115504_b0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/ci00046a002","article-title":"Atom pairs as molecular features in structure-activity studies: definition and applications","volume":"25","author":"Carhart","year":"1985","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115504_b0140","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/ci990423o","article-title":"Strategic pooling of compounds for high-throughput screening","volume":"39","author":"Hann","year":"1999","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"27","key":"10.1016\/j.bcp.2023.115504_b0145","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1002\/anie.201702816","article-title":"Privileged structures revisited","volume":"56","author":"Schneider","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins"},{"issue":"10","key":"10.1016\/j.bcp.2023.115504_b0155","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/jcc.20933","article-title":"The generalized Born\/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area","volume":"29","author":"Labute","year":"2008","journal-title":"J. Comput. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2023.115504_b0160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.tetlet.2011.01.002","article-title":"Olefin cyclopropanation with aryl diazocompounds upon catalysis by a dirhodium(II) complex","volume":"52","author":"Verdecchia","year":"2011","journal-title":"Tetrahedron Lett."},{"issue":"9","key":"10.1016\/j.bcp.2023.115504_b0165","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/jm0204800","article-title":"Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor","volume":"46","author":"Muthyala","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115504_b0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1015582104282","article-title":"Reactions of aliphatic diazo compounds: IV. Reaction of Diphenyldiazomethane with substituted imides of maleic and itaconic acids","volume":"38","author":"Molchanov","year":"2002","journal-title":"Russ. J. Org. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2023.115504_b0175","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1111\/bph.13256","article-title":"A novel multi-parameter assay to dissect the pharmacological effects of different modes of integrin \u03b1L\u03b22 inhibition in whole blood","volume":"172","author":"Welzenbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115504_b0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.bcp.2023.115504_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104557","article-title":"Research progress in biological activities of succinimide derivatives","volume":"108","author":"Zhao","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2023.115504_b0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.bcp.2023.115504_b0195","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1073\/pnas.0810844106","article-title":"Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance","volume":"106","author":"Li","year":"2009","journal-title":"PNAS"},{"issue":"49","key":"10.1016\/j.bcp.2023.115504_b0200","doi-asserted-by":"crossref","first-page":"42115","DOI":"10.1074\/jbc.M111.282830","article-title":"The C-terminal \u03b1I domain linker as a critical structural element in the conformational activation of \u03b1I integrins","volume":"286","author":"Weitz-Schmidt","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2023.115504_b0205","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/emboj.2011.333","article-title":"Regulation of integrin affinity on cell surfaces","volume":"30","author":"Sch\u00fcrpf","year":"2011","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.bcp.2023.115504_b0210","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"1","author":"Berger","year":"2009","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1083\/jcb.201110023","article-title":"Structural specializations of \u03b1(4)\u03b2(7), an integrin that mediates rolling adhesion","volume":"196","author":"Yu","year":"2012","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115504_b0220","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1038\/s41467-020-18397-6","article-title":"Translational pharmacology of an inhaled small molecule \u03b1v\u03b26 integrin inhibitor for idiopathic pulmonary fibrosis","volume":"11","author":"John","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2023.115504_b0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fphar.2019.00039","article-title":"Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease","volume":"1","author":"Lichnog","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115504_b0230","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/01.ATV.0000255307.65939.59","article-title":"A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb\/IIIa) antagonists","volume":"27","author":"Bassler","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0235","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2023.115504_b0240","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1074-7613(04)00082-2","article-title":"Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction","volume":"20","author":"Salas","year":"2004","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.bcp.2023.115504_b0245","doi-asserted-by":"crossref","first-page":"10876","DOI":"10.1074\/jbc.M512472200","article-title":"Transition from rolling to firm adhesion can be mimicked by extension of integrin alphaLbeta2 in an intermediate affinity state","volume":"281","author":"Salas","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115504_b0250","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2005-06-2303","article-title":"Dynamic shifts in LFA-1 affinity regulate neutrophil rolling, arrest, and transmigration on inflamed endothelium","volume":"107","author":"Green","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bcp.2023.115504_b0255","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/anie.201310240","article-title":"Identification and X-ray co-crystal structure of a small-molecule activator of LFA-1-ICAM-1 binding","volume":"53","author":"Hintersteiner","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"9","key":"10.1016\/j.bcp.2023.115504_b0260","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2016-03-705160","article-title":"LFA-1 integrin antibodies inhibit leukocyte \u03b14\u03b21-mediated adhesion by intracellular signaling","volume":"128","author":"Gr\u00f6nholm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2023.115504_b0265","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/1547691X.2015.1019596","article-title":"Differential effects of volatile anesthetics on leukocyte integrin macrophage-1 antigen","volume":"13","author":"Jung","year":"2016","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.bcp.2023.115504_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.702529","article-title":"Identification of oleanolic acid as allosteric agonist of integrin \u03b1(M) by combination of in silico modeling and in vitro analysis","volume":"12","author":"Jin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115504_b0275","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1016\/j.bbagen.2013.02.018","article-title":"Small molecule agonists of integrin CD11b\/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury","volume":"1830","author":"Faridi","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2023.115504_b0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(06)91003-7","article-title":"Targeting integrin structure and function in disease","volume":"91","author":"Staunton","year":"2006","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115504_b0285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","article-title":"The integrins","volume":"8","author":"Takada","year":"2007","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115504_b0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/17460441.2022.2017876","article-title":"Hidden allosteric sites and De-Novo drug design","volume":"17","author":"Rehman","year":"2022","journal-title":"Expert Opin. Drug Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:16:07Z","timestamp":1762096567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223000953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":58,"alternative-id":["S0006295223000953"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115504","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric targeting resolves limitations of earlier LFA-1 directed modalities","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115504"}}